NHS
Pan Mersey
Area Prescribing Committee

SOLRIAMFETOL HYDROCHLORIDE tablets (Sunosi® ▼) for excessive daytime sleepiness in obstructive sleep apnoea

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of SOLRIAMFETOL HYDROCHLORIDE tablets (Sunosi® ▼) for excessive daytime sleepiness in obstructive sleep apnoea.

GREY

Solriamfetol hydrochloride is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP).[1]

> This recommendation will be reviewed when the NICE TA is published.

In the meantime, treatment of excessive daytime sleepiness in OSA should continue to follow national guidance and local pathways:

> NICE Clinical Knowledge Summary: Obstructive sleep apnoea syndrome (April 2015)

References

1. Jazz Pharmaceuticals UK. Summary of Product Characteristics, Sunosi 75 mg film-coated tablets; 21 August 2020. Accessed online 12 October 2020.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.

Date of issue: 19 Oct 2020 Prescribing policy statement
Review date: Oct 2022 (or earlier if there is significant new evidence relating to this recommendation) Version: 1.0
APC administration provided by Midlands and Lancashire Commissioning Support Unit